Glenmark in exclusive distribution agreement with Cediprof

Glenmark expects to commence distribution of the product in the US during the second half of 2023 Glenmark Pharmaceuticals, USA and Cediprof (a part of the Neolpharma Pharmaceutical Group family of companies) have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, the generic version of Adderall1 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women’s Health. Glenmark expects to commence distribution of the product in the US during the second half of 2023. This product has long been on FDA’s shortage list. Brendan O’Grady, CEO, Glenmark Global Formulations Business said, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is pleased to be able to alleviate the shortage this country is facing by partnering with Cediprof and Neol."